Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.
about
Direct detection of alternative open reading frames translation products in human significantly expands the proteomeA new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcriptionTranslation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineageA gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytesIdentification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytesTumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccinesDRiPs solidify: progress in understanding endogenous MHC class I antigen processingDatabase of T cell-defined human tumor antigens: the 2013 updateDNA vaccine for cancer immunotherapyNovel tumor antigens identified by autologous antibody screening of childhood medulloblastoma cDNA librariesThe XAGE family of cancer/testis-associated genes: alignment and expression profile in normal tissues, melanoma lesions and Ewing's sarcomaAn unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactionsInfluence of HAART on alternative reading frame immune responses over the course of HIV-1 infectionMUC1-ARF-A Novel MUC1 Protein That Resides in the Nucleus and Is Expressed by Alternate Reading Frame Translation of MUC1 mRNA.A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia.The class I antigen-processing pathway for the membrane protein tyrosinase involves translation in the endoplasmic reticulum and processing in the cytosolA processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma.CTL escape mediated by proteasomal destruction of an HIV-1 cryptic epitopeT cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product.Autoantibody approach for serum-based detection of head and neck cancer.Viral adaptation to immune selection pressure by HLA class I-restricted CTL responses targeting epitopes in HIV frameshift sequences.Cytotoxic T lymphocytes to endogenous mouse retroviruses and mechanisms of retroviral escape.Human tumor antigens for cancer vaccine development.Serum prognostic biomarkers in head and neck cancer patients.An out-of-frame overlapping reading frame in the ataxin-1 coding sequence encodes a novel ataxin-1 interacting proteinAutoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".Peptide vaccines for cancer.Progress in the development of immunotherapy for the treatment of patients with cancer.Assumptions of the tumor 'escape' hypothesis.Development of effective immunotherapy for the treatment of patients with cancer.Impaired memory CD8 T cell responses against an immunodominant retroviral cryptic epitopeNon-conventional sources of peptides presented by MHC class I.The melanoma antigens MELOE-1 and MELOE-2 are translated from a bona fide polycistronic mRNA containing functional IRES sequences.The HIV-1 antisense protein (ASP) induces CD8 T cell responses during chronic infection.Immunotherapy of cancer by active vaccination: does allogeneic bone marrow transplantation after non-myeloablative conditioning provide a new option?Current advances in T-cell-based cancer immunotherapyMechanisms of immunization against cancer using chimeric antigens.MHC-bound antigens and proteomics for novel target discovery.Identification of human tumor antigens and its implications for diagnosis and treatment of cancer.Developing recombinant and synthetic vaccines for the treatment of melanoma.
P2860
Q21132658-CB26E8FB-644B-4A63-99B8-4AA9C9D4B90AQ22010943-12CF8A7C-DB28-4C4F-A0F7-AC5ACFF1933EQ24646800-7E2CB2BD-C41A-4414-B8DC-87DD787566E7Q24647420-BB9BB0D0-933C-4260-9C7B-615EB55BE9DFQ24647904-6E48C0A0-8E40-4D04-9601-68651DCF96C4Q24804837-9B34C308-0AFE-4120-8809-99DEA1A3FF0FQ27006750-B858DE80-7DBF-4EB9-91FF-C14193C86095Q27022422-F9BA4FFB-66D6-43D3-96BE-3D9F389F29C9Q28080919-FF24A9F3-27DE-4AAE-9CE8-A44FD80EC0BEQ28178383-1C025249-6DA1-4F60-AB72-3453551C18B0Q28216604-E6A573DA-04F4-49D2-BD5B-43353520A05AQ28264336-19F82010-88E3-4C85-8F0C-FBAB2C0ADB9AQ28480902-CBD685A6-CE5D-4556-B21D-80F4BA81C235Q30008839-88E82FBB-7185-4FA6-829B-E64328C71C6BQ30274634-0F550A1F-5BF7-422A-82D6-5B37498FF19EQ30442820-5316D5A4-A885-477C-BA6F-6A5EBCED9565Q30865419-0FF15B60-2DD6-4D94-9A27-3659F53A0240Q31010282-E0EF24CF-BF14-442D-9254-1727B902F307Q33202641-183034E0-3455-40A0-B043-AF9142286D5DQ33305783-8D45D4DD-5E73-467C-A40C-6E038BC11EDBQ33615145-BE55A058-A31A-473A-B2DD-3D8089D9CC31Q33683425-7CAC313F-7CFF-4695-8167-745103F81442Q33776127-7DA3AEA8-1363-4481-AE09-CD92AA5D3F88Q34032646-47897620-F861-42CA-A69F-59AFAE0AD548Q34037160-1EEC00D5-E4BA-411E-89CF-4744FFA4703DQ34276512-D9A25EF1-29E6-4457-BDBF-8EF3AF0C60F6Q34568992-506BBD4A-DCDF-4E4C-B138-4CEB40E5D2F9Q34570245-D7C2850B-A071-4253-9E8F-7C141645BD5FQ34583258-1B12E72F-AFC4-490C-8376-DE9E678DF30BQ34647354-8F494739-2BE3-4034-872B-820CCAE5D220Q34699353-7D4B9975-F234-4127-B8D6-1AA34E74AA8CQ34768462-818B894B-C36E-4261-A661-C7F0263FB3A7Q35005458-74C70738-B3A7-4A8C-BCFD-8D34A73EE7CAQ35105393-31635DBC-490E-42E8-A862-75919FF4CDB7Q35142329-CAA7C20C-A5A4-4DC7-8049-515CBF9FDCC0Q35215158-E95557B0-4BEC-4025-B038-980D65C3C19CQ35442846-5523991C-D20A-48AE-BED1-BBCBB31AB2EEQ35911151-EBB2E963-AA42-4570-BDD9-19EDA51F549CQ35927479-617481D0-E522-43C6-9DFE-CB4D62B177D6Q35946196-F52CC945-5F06-4DC4-B310-EF415788AC13
P2860
Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Utilization of an alternative ...... a novel human cancer antigen.
@ast
Utilization of an alternative ...... a novel human cancer antigen.
@en
type
label
Utilization of an alternative ...... a novel human cancer antigen.
@ast
Utilization of an alternative ...... a novel human cancer antigen.
@en
prefLabel
Utilization of an alternative ...... a novel human cancer antigen.
@ast
Utilization of an alternative ...... a novel human cancer antigen.
@en
P2093
P2860
P356
P1476
Utilization of an alternative ...... a novel human cancer antigen.
@en
P2093
Kawakami Y
Parkhurst MR
Robbins PF
Rosenberg SA
P2860
P304
P356
10.1084/JEM.183.3.1131
P407
P577
1996-03-01T00:00:00Z